Literature DB >> 29883308

Hydroxychloroquine: An old drug with new relevance.

Eugen Alexander Shippey1, Vanya D Wagler2, Angelique N Collamer3.   

Abstract

Hydroxychloroquine is an immunomodulatory drug that has been used for 60 years to treat malaria and autoimmune diseases such as systemic lupus erythematosus and inflammatory arthritis, and potential new uses and benefits continue to emerge. Toxicity concerns have been addressed with updated prescribing recommendations.
Copyright © 2018 Cleveland Clinic.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29883308     DOI： 10.3949/ccjm.85a.17034

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


  34 in total

1.  Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.

Authors:  Pascale M Abena; Eric H Decloedt; Emmanuel Bottieau; Fatima Suleman; Prisca Adejumo; Nadia A Sam-Agudu; Jean-Jacques Muyembe TamFum; Moussa Seydi; Serge P Eholie; Edward J Mills; Oscar Kallay; Alimuddin Zumla; Jean B Nachega
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

Review 2.  Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials.

Authors:  Paul Eze; Kenechukwu N Mezue; Chidozie U Nduka; Ijeoma Obianyo; Obiora Egbuche
Journal:  Am J Cardiovasc Dis       Date:  2021-02-15

Review 3.  Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.

Authors:  Mohitosh Biswas; Nares Sawajan; Thanyada Rungrotmongkol; Kamonpan Sanachai; Maliheh Ershadian; Chonlaphat Sukasem
Journal:  Front Pharmacol       Date:  2022-02-18       Impact factor: 5.810

4.  Hydroxychloroquine and Fabry Disease: Three Case Reports Examining an Unexpected Pathologic Link and a Review of the Literature.

Authors:  Rouhin Sen; Kathleen Borghoff; Kirk W Foster; Stanley J Radio; Alan Erickson; Michelene Hearth-Holmes
Journal:  Case Rep Rheumatol       Date:  2022-07-11

5.  Effect of hydroxychloroquine on glucose control in patients with and without diabetes: a systematic review and meta-analysis of randomized controlled clinical trials.

Authors:  Luis E Simental-Mendía; Mario Simental-Mendía; Adriana Sánchez-García; Enrique Linden-Torres
Journal:  Eur J Clin Pharmacol       Date:  2021-05-19       Impact factor: 2.953

Review 6.  Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.

Authors:  Slobodan Rendic; Frederick Peter Guengerich
Journal:  Curr Drug Metab       Date:  2020       Impact factor: 3.731

Review 7.  Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.

Authors:  Jimin Xu; Yu Xue; Richard Zhou; Pei-Yong Shi; Hongmin Li; Jia Zhou
Journal:  Med Res Rev       Date:  2020-12-05       Impact factor: 12.944

8.  [Drug-induced toxidermia in a patient receiving hydroxychloroquine as systemic therapy for primary Gougerot-Sjögren syndrome: a case report].

Authors:  Ansumana Mohammed Keita; Mouna Zahlane; Laila Benjilali; Lamiaa Essaadouni
Journal:  Pan Afr Med J       Date:  2021-03-18

Review 9.  Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.

Authors:  Safaet Alam; Taslima Binte Kamal; Md Moklesur Rahman Sarker; Jin-Rong Zhou; S M Abdur Rahman; Isa Naina Mohamed
Journal:  Front Pharmacol       Date:  2021-06-14       Impact factor: 5.810

Review 10.  Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic.

Authors:  Bogna Grygiel-Górniak
Journal:  Clin Rheumatol       Date:  2021-07-03       Impact factor: 3.650
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.